HOME > Investors > Press Releases
2010-04-27
ViroMed Submits Phase III Trial Application of VM501 for Chemotherapy-Induced Thrombocytopenia in China
2010-04-12
ViroMed’s DNA Medicine Receives Phase II Approval for PAD in Korea
2009-11-12
ViroMed-Helixir Merger Completed
2009-10-26
ViroMed Presents Results of Multinational VM202 Trials at Cardiovascular Conference in China
2009-07-17
ViroMed Appoints Yongsoo Kim as Co-CEO
11 12 13 14 15 16 17 18 19 20